Mohamed-Reda Benmebarek
Overview
Explore the profile of Mohamed-Reda Benmebarek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benmebarek M, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer K, et al.
Immunity
. 2025 Mar;
PMID: 40088889
Anti-vascular endothelial growth factor (VEGF) treatment has shown clinical activity together with immune checkpoint blockade (ICB), but the exact mechanism is not known. We show that VEGF blockade in combination...
2.
Myojin Y, Babaei S, Trehan R, Hoffman C, Kedei N, Ruf B, et al.
Gut
. 2025 Feb;
PMID: 39965889
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. Objective: To study immune...
3.
Trehan R, Zhu X, Huang P, Wang X, Soliman M, Strepay D, et al.
bioRxiv
. 2024 Oct;
PMID: 39372792
Functional tumor-specific CD8+ T cells are essential for an effective anti-tumor immune response and the efficacy of immune checkpoint inhibitor therapy. In comparison to other organ sites, we found higher...
4.
Bauer K, Trehan R, Ruf B, Myojin Y, Benmebarek M, Ma C, et al.
bioRxiv
. 2024 Feb;
PMID: 38328040
Liver cancer ranks amongst the deadliest cancers. Nerves have emerged as an understudied regulator of tumor progression. The parasympathetic vagus nerve influences systemic immunity via acetylcholine (ACh). Whether cholinergic neuroimmune...
5.
Myojin Y, McCallen J, Ma C, Bauer K, Ruf B, Benmebarek M, et al.
JHEP Rep
. 2024 Jan;
6(1):100959.
PMID: 38192537
Backgrounds & Aims: The efficacy of immune checkpoint inhibitor (ICI) therapy for liver cancer remains limited. As the hypoxic liver environment regulates adenosine signaling, we tested the efficacy of adenosine...
6.
Green B, Myojin Y, Ma C, Ruf B, Ma L, Zhang Q, et al.
Gut
. 2023 Sep;
73(3):509-520.
PMID: 37770128
Objective: Liver metastases are often resistant to immune checkpoint inhibitor therapy (ICI) and portend a worse prognosis compared with metastases to other locations. Regulatory T cells (Tregs) are one of...
7.
Ruf B, Bruhns M, Babaei S, Kedei N, Ma L, Revsine M, et al.
Cell
. 2023 Aug;
186(17):3686-3705.e32.
PMID: 37595566
Mucosal-associated invariant T (MAIT) cells represent an abundant innate-like T cell subtype in the human liver. MAIT cells are assigned crucial roles in regulating immunity and inflammation, yet their role...
8.
Lorenzini T, Cadilha B, Obeck H, Benmebarek M, Markl F, Michaelides S, et al.
Br J Cancer
. 2023 Jul;
129(4):696-705.
PMID: 37400680
Background: In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a...
9.
Markl F, Benmebarek M, Keyl J, Cadilha B, Geiger M, Karches C, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37208128
Background: Melanoma is an immune sensitive disease, as demonstrated by the activity of immune check point blockade (ICB), but many patients will either not respond or relapse. More recently, tumor...
10.
Gottschlich A, Thomas M, Grunmeier R, Lesch S, Rohrbacher L, Igl V, et al.
Nat Biotechnol
. 2023 Mar;
41(11):1618-1632.
PMID: 36914885
Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid...